Schrödinger, Inc.

Schrödinger, Inc. is an international scientific software company that specializes in developing computational tools and software for drug discovery and materials science.

Schrödinger
TypePublic
Nasdaq: SDGR
Russell 2000 Component
S&P 600 Component
Industry
Founded1990
FounderRichard A. Friesner,
William A. Goddard III
HeadquartersNew York, NY
Area served
Worldwide
Key people
Ramy Farid
(President & CEO)
Michael Lynton
(Chairman)
Products
  • Advanced computational platform for drug discovery and materials science
  • LiveDesign
  • PyMOL
RevenueIncrease $181 Million (2022)[1]
Number of employees
1015
Websitewww.schrodinger.com

Schrodinger's software is used by pharmaceutical companies, biotech firms, and academic researchers to simulate and model the behavior of molecules at the atomic level. This accelerates the design and develops new drugs and materials more efficiently, reducing the time and cost of bringing them to market.

Schrodinger's software tools include molecular dynamics simulations, quantum mechanics calculations, and virtual screening tools. The company also offers consulting services and collaborates with partners in the industry to advance the field of computational chemistry and drug discovery.

Products and services

Schrödinger's computational platforms evaluate compounds in silico, with experimental accuracy on properties such as binding affinity and solubility. The company's products include molecular modeling programs, and an Enterprise Informatics Platform named LiveDesign, which is intended to facilitate communication among interdisciplinary research teams.[2]

In addition to computational platforms, Schrödinger develops custom software for enterprises, as well as training, computer-cluster design and implementation, and research-based drug discovery projects.[3][4]

Partners

Schrödinger's partners include pharmaceutical companies, including Bayer,[5][6] Takeda,[7] and more.

Nimbus Therapeutics, co-founded by Schrödinger, uses Schrödinger's drug screening and design platform for drug discovery. In 2016, Nimbus Therapeutics sold an Acetyl-CoA carboxylase (ACC) inhibitor designed by Schrödinger to Gilead Sciences in a deal worth up to $1.2 billion.[8] As of spring 2019 the ACC inhibitor was moving through late-stage clinical trials in NASH.[9]

Recognition

In November 2013, Schrödinger, in collaboration with Cycle Computing and the University of Southern California, set a record for the world's largest and fastest cloud computing run by using 156,000 cores on Amazon Web Services to screen over 205,000 molecules for materials science research.[10] That work was a follow-up to a 2012 collaboration which saw Cycle Computing creating a 50,000 core virtual supercomputer using Amazon and Schrödinger's infrastructure, which at that time was used to analyze 2.1 million compounds in 3 hours.[11]

References
  1. "Schrödinger Reports First Quarter 2022 Financial Results". ir.schrodinger.com (Press release). May 4, 2022. Archived from the original on February 21, 2023. Retrieved June 15, 2023.
  2. "LiveDesign". LiveDesign.
  3. Booth, Bruce (June 27, 2013). "The Nimbus Experiment: Structure-Based Drug Deals". Forbes.
  4. "Schrodinger and Professor Mark E. Thompson (USC) Announce Research Collaboration to Enable Computer'Aided Design of Organic Semiconductor Materials" (Press release). June 2013. Retrieved October 20, 2014.
  5. "Schrödinger and Bayer Collaborate to Co-Develop de novo Design Technology to Accelerate Drug Discovery". Schrödinger (Press release). January 8, 2020. Retrieved March 12, 2021.
  6. Hillisch, Alexander (January 6, 2022). "A Digital Platform for Molecular Design: Inside the Schrödinger-Bayer Collaboration". extrapolations.com (Press release). Archived from the original on February 21, 2023. Retrieved June 15, 2023.
  7. Liu, Angus (July 20, 2017). "Takeda, Schrödinger form multiprogram drug discovery pact". FierceBiotech (Press release).
  8. Flood, Amy; O’Brien, Patrick; Melone, Liz (April 4, 2016). "Gilead Sciences Announces Acquisition of Nimbus Therapeutics' Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases". www.businesswire.com (Press release). Retrieved June 19, 2019.
  9. "Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)". www.gilead.com (Press release). Retrieved June 19, 2019.
  10. Shankland, Stephen (November 12, 2013). "Supercomputing simulation employs 156,000 Amazon processor cores". CNet.
  11. Brodkin, Jon (April 19, 2012). "$4,829-per-hour supercomputer built on Amazon cloud to fuel cancer research". Ars Technica.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.